Concord Wealth Partners Viking Therapeutics, Inc. Transaction History
Concord Wealth Partners
- $603 Million
- Q4 2024
A detailed history of Concord Wealth Partners transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Concord Wealth Partners holds 5 shares of VKTX stock, worth $141. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5
Previous 5
-0.0%
Holding current value
$141
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
467Shares Held
65.8MCall Options Held
5.84MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$288 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$171 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$139 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$73.5 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$61.1 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.17B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...